ADPT
ADAPTIVE BIOTECHNOLOGIES CORPORATIONMarquee-fund ownership over time
This quarter's activity
New positions opened
Positions exited
None.
Current holders
Sorted by tenure (longest first)| Fund | First disclosed | Held | Entry price | Latest close | Return on entry |
|---|---|---|---|---|---|
| Viking Global Investors | Q3 2019 | 28Q | $43 | $13 | -71% |
| Renaissance Technologies re-entered | Q3 2024(8Q snapshot) | 7Q | $4.47 | $13 | +184% |
| Citadel Advisors | Q3 2024(8Q snapshot) | 7Q | $4.40 | $13 | +189% |
| AQR Capital Management | Q3 2024(8Q snapshot) | 7Q | $4.40 | $13 | +189% |
| Millennium Management | Q3 2024(8Q snapshot) | 7Q | $4.40 | $13 | +189% |
| Two Sigma Investments re-entered | Q4 2024(8Q snapshot) | 6Q | $5.58 | $13 | +128% |
| Point72 Asset Management re-entered | Q4 2024(8Q snapshot) | 6Q | $5.58 | $13 | +128% |
| D.E. Shaw | Q3 2025(8Q snapshot) | 3Q | $13 | $13 | -2% |
| Bridgewater Associates | Q4 2025 | 2Q | $14 | $13 | -10% |
“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.
Past holders
Funds that exited at some point| Fund | Last entry | Exited | Entry → Exit | Return |
|---|---|---|---|---|
| Maverick Capital | Q2 2021 | Q3 2021 | → $31 | -10% |
| Coatue Management | Q1 2020 | Q2 2020 | → $38 | +21% |
Insider activity
Form 4 — officers, directors, 10%+ ownersFiled within two business days of each transaction by anyone with material insider status at Adaptive Biotechnologies Corp. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.
30d / 90d windows measured from Jun 8, 2026 — the most recent Form 4 on file — not from today.
- Form 40001780660-26-000015Jun 8, 2026
- Form 40001820885-26-000008Jun 8, 2026
- Form 40001780662-26-000013May 20, 2026
- Form 40001780664-26-000032Apr 29, 2026
- Form 40001780664-26-000030Apr 24, 2026
- Form 40001780664-26-000028Apr 21, 2026
- Form 40001780664-26-000026Apr 16, 2026
- Form 40001780664-26-000024Apr 13, 2026
- Form 40001780660-26-000013Apr 10, 2026
- Form 40001780851-26-000011Apr 10, 2026
- Form 40001780649-26-000011Apr 8, 2026
- Form 40001780664-26-000022Apr 8, 2026
- Form 40001780664-26-000020Apr 2, 2026
- Form 40001780664-26-000018Mar 31, 2026
- Form 40001780664-26-000016Mar 26, 2026
Fundamentals
XBRL · ADAPTIVE BIOTECHNOLOGIES CORPORATIONAnnual figures sourced directly from ADAPTIVE BIOTECHNOLOGIES CORPORATION's 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.
Recent SEC filings
10-K · 10-Q · 8-K · 13D/G · proxyThe most recent material filings for Adaptive Biotechnologies Corp — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.
- 8-KMaterial eventJun 9, 2026
- 10-QQuarterly reportMay 5, 2026
- 8-KMaterial eventMay 5, 2026
- DEF 14AProxy statementApr 24, 2026
- 10-KAnnual reportFeb 26, 2026
- 8-KMaterial eventFeb 5, 2026
- 8-KMaterial eventJan 12, 2026
- 8-KMaterial eventDec 30, 2025
- 10-QQuarterly reportNov 5, 2025
- 8-KMaterial eventNov 5, 2025
- 8-KMaterial eventAug 18, 2025
- 10-QQuarterly reportAug 5, 2025
- 8-KMaterial eventAug 5, 2025
- 8-KMaterial eventJun 12, 2025
- 10-QQuarterly reportMay 1, 2025
Trade history
Every open→close lifecycle across tracked funds| Fund | Open date | Close date | Open price | Close price / current | Return |
|---|---|---|---|---|---|
| Two Sigma Investments | Q2 2026 | open | $13 | $13 | -1% |
| Renaissance Technologies | Q2 2026 | open | $13 | $13 | -4% |
| Bridgewater Associates | Q4 2025 | open | $14 | $15 | +7% |
| D.E. Shaw | Q3 2025 | open | $13 | $13 | -2% |
| Point72 Asset Management | Q3 2025 | open | $13 | $13 | -2% |
| Two Sigma Investments | Q4 2024 | Q2 2025 | $5.58 | $8.91 | +60% |
| Point72 Asset Management | Q4 2024 | Q2 2025 | $5.58 | $8.91 | +60% |
| Citadel Advisors | Q3 2024 | open | $4.40 | $13 | +189% |
| AQR Capital Management | Q3 2024 | open | $4.40 | $13 | +189% |
| Millennium Management | Q3 2024 | open | $4.40 | $13 | +189% |
| Renaissance Technologies | Q3 2024 | Q1 2026 | $4.47 | $16 | +248% |
| Maverick Capital | Q2 2021 | Q3 2021 | $34 | $31 | -10% |
| Coatue Management | Q1 2020 | Q2 2020 | $31 | $38 | +21% |
| Viking Global Investors | Q3 2019 | open | $43 | $15 | -65% |
- Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
- Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
- “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
- Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
- Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.